NASDAQ:MITO Stealth BioTherapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stealth BioTherapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. $0.28 -0.01 (-3.46%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$0.28▼$0.3050-Day Range$0.18▼$0.4952-Week Range$0.16▼$1.62Volume212,067 shsAverage Volume1.88 million shsMarket Capitalization$16.73 millionP/E RatioN/ADividend YieldN/APrice Target$2.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MITO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MITO Stock Forecast (MarketRank)Overall MarketRank™1.68 out of 5 starsMedical Sector916th out of 1,411 stocksPharmaceutical Preparations Industry458th out of 672 stocksAnalyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingStealth BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.25, Stealth BioTherapeutics has a forecasted upside of 706.5% from its current price of $0.28.Amount of Analyst CoverageStealth BioTherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.3 Community Rank Outperform VotesStealth BioTherapeutics has received 87 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStealth BioTherapeutics has received 50 “underperform” votes. (Add your “underperform” vote.)Community SentimentStealth BioTherapeutics has received 63.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Stealth BioTherapeutics and other stocks. Vote “Outperform” if you believe MITO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MITO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStealth BioTherapeutics does not currently pay a dividend.Dividend GrowthStealth BioTherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stealth BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.52% of the stock of Stealth BioTherapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stealth BioTherapeutics are expected to grow in the coming year, from ($0.06) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stealth BioTherapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stealth BioTherapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Stealth BioTherapeutics (NASDAQ:MITO)Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.Read More MITO Stock News HeadlinesJune 17, 2022 | americanbankingnews.comStealth BioTherapeutics (NASDAQ:MITO) Receives "Buy" Rating from HC WainwrightJune 14, 2022 | markets.businessinsider.comStealth Granted Pre-NDA Meeting For Elamipretide To Treat Barth SyndromeJune 14, 2022 | seekingalpha.comStealth Bio rises on pre-NDA meeting for candidate targeting rare heart conditionJune 14, 2022 | finance.yahoo.comStealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth SyndromeJune 13, 2022 | americanbankingnews.comStealth BioTherapeutics Corp (NASDAQ:MITO) Sees Large Increase in Short InterestJune 11, 2022 | americanbankingnews.comStealth BioTherapeutics (NASDAQ:MITO) Stock Rating Reaffirmed by HC WainwrightJune 8, 2022 | finance.yahoo.comHealthcare Breakthroughs: NVAX, MITO, LMLLF, NMLSF; Life Sciences Leaders Report Latest Advances in Vaccines, Novel Therapeutics for Autism, Neurodegenerative, Oncology, and GlaucomaJune 8, 2022 | finance.yahoo.comStealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration SymposiumMay 31, 2022 | seekingalpha.comStealth Bio's elamipretide gets EMA orphan drug status for muscle disorderMay 31, 2022 | finance.yahoo.comStealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion SyndromeMay 23, 2022 | finance.yahoo.comStealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022May 12, 2022 | seekingalpha.comStealth Bio climbs on FDA’s Orphan Drug status for lead asset in muscular disorderMay 3, 2022 | msn.comMITO: Positive Data Despite Miss for MITOSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MITO CUSIPN/A CIK1696396 Webwww.stealthbt.com Phone617-600-6888FaxN/AEmployees29Year FoundedN/ACompany Calendar Last Earnings5/18/2022Today6/26/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$2.25 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+706.5%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52.53 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-142.81% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.68 Sales & Book Value Annual Sales$21.09 million Price / Sales0.79 Cash FlowN/A Price / Cash FlowN/A Book Value($0.79) per share Price / Book-0.35Miscellaneous Outstanding Shares59,970,000Free FloatN/AMarket Cap$16.73 million OptionableNot Optionable Beta2.09 Stealth BioTherapeutics Frequently Asked Questions Should I buy or sell Stealth BioTherapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Stealth BioTherapeutics stock. View analyst ratings for Stealth BioTherapeutics or view top-rated stocks. What is Stealth BioTherapeutics' stock price forecast for 2022? 2 Wall Street research analysts have issued 1 year price targets for Stealth BioTherapeutics' shares. Their MITO stock forecasts range from $1.50 to $3.00. On average, they anticipate Stealth BioTherapeutics' share price to reach $2.25 in the next year. This suggests a possible upside of 706.5% from the stock's current price. View analysts' price targets for Stealth BioTherapeutics or view top-rated stocks among Wall Street analysts. How has Stealth BioTherapeutics' stock price performed in 2022? Stealth BioTherapeutics' stock was trading at $0.83 at the start of the year. Since then, MITO shares have decreased by 66.4% and is now trading at $0.2790. View the best growth stocks for 2022 here. Are investors shorting Stealth BioTherapeutics? Stealth BioTherapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 1,480,000 shares, an increase of 95.4% from the May 15th total of 757,400 shares. Based on an average daily volume of 2,470,000 shares, the short-interest ratio is currently 0.6 days. View Stealth BioTherapeutics' Short Interest. When is Stealth BioTherapeutics' next earnings date? Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Stealth BioTherapeutics. How were Stealth BioTherapeutics' earnings last quarter? Stealth BioTherapeutics Corp (NASDAQ:MITO) issued its quarterly earnings results on Wednesday, May, 18th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.10. View Stealth BioTherapeutics' earnings history. Who are Stealth BioTherapeutics' key executives? Stealth BioTherapeutics' management team includes the following people: Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 57)Mr. Henry Hess, Chief Legal CounselDr. Ben R. Bronstein M.D., Chief Medical Officer (Age 72)Mr. Brian Hotchkiss, VP of Bus. Devel. & Strategy Who are some of Stealth BioTherapeutics' key competitors? Some companies that are related to Stealth BioTherapeutics include Xilio Therapeutics (XLO), Infinity Pharmaceuticals (INFI), PLx Pharma (PLXP), BioLineRx (BLRX), Opiant Pharmaceuticals (OPNT), Athersys (ATHX), NightHawk Biosciences (NHWK), Sensei Biotherapeutics (SNSE), eFFECTOR Therapeutics (EFTR), Orgenesis (ORGS), Decibel Therapeutics (DBTX), Lumos Pharma (LUMO), Eyenovia (EYEN), IMV (IMV) and LifeVantage (LFVN). View all of MITO's competitors. What other stocks do shareholders of Stealth BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB), Soleno Therapeutics (SLNO) and Arbutus Biopharma (ABUS). When did Stealth BioTherapeutics IPO? (MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets served as the underwriters for the IPO and Nomura was co-manager. What is Stealth BioTherapeutics' stock symbol? Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO." How do I buy shares of Stealth BioTherapeutics? Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Stealth BioTherapeutics' stock price today? One share of MITO stock can currently be purchased for approximately $0.28. How much money does Stealth BioTherapeutics make? Stealth BioTherapeutics (NASDAQ:MITO) has a market capitalization of $16.73 million and generates $21.09 million in revenue each year. The company earns $-52.53 million in net income (profit) each year or ($0.52) on an earnings per share basis. How many employees does Stealth BioTherapeutics have? Stealth BioTherapeutics employs 29 workers across the globe. How can I contact Stealth BioTherapeutics? Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The official website for Stealth BioTherapeutics is www.stealthbt.com. The company can be reached via phone at 617-600-6888 or via email at [email protected]. This page (NASDAQ:MITO) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
